BR112015008418A2 - uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae - Google Patents
uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniaeInfo
- Publication number
- BR112015008418A2 BR112015008418A2 BR112015008418A BR112015008418A BR112015008418A2 BR 112015008418 A2 BR112015008418 A2 BR 112015008418A2 BR 112015008418 A BR112015008418 A BR 112015008418A BR 112015008418 A BR112015008418 A BR 112015008418A BR 112015008418 A2 BR112015008418 A2 BR 112015008418A2
- Authority
- BR
- Brazil
- Prior art keywords
- streptococcus pneumoniae
- immunogenic composition
- targeted
- individual
- methods
- Prior art date
Links
- 241000193998 Streptococcus pneumoniae Species 0.000 title abstract 8
- 229940031000 streptococcus pneumoniae Drugs 0.000 title abstract 8
- 230000002163 immunogen Effects 0.000 title abstract 5
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 230000001662 opsonic effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261714956P | 2012-10-17 | 2012-10-17 | |
| US201261714942P | 2012-10-17 | 2012-10-17 | |
| GBGB1218660.7A GB201218660D0 (en) | 2012-10-17 | 2012-10-17 | Immunogenic composition |
| US13/826,696 US9561268B2 (en) | 2012-10-17 | 2013-03-14 | Immunogenic composition |
| US13/826,932 US20140193451A1 (en) | 2012-10-17 | 2013-03-14 | Immunogenic composition |
| US13/827,203 US20140105927A1 (en) | 2012-10-17 | 2013-03-14 | Immunogenic composition |
| PCT/EP2013/071483 WO2014060389A2 (en) | 2012-10-17 | 2013-10-15 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008418A2 true BR112015008418A2 (pt) | 2017-07-04 |
Family
ID=53008966
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008418A BR112015008418A2 (pt) | 2012-10-17 | 2013-10-15 | uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae |
| BR112015008419-2A BR112015008419B1 (pt) | 2012-10-17 | 2013-10-15 | Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina |
| BR112015008417A BR112015008417A8 (pt) | 2012-10-17 | 2013-10-15 | composição imunogênica, vacina, e, uso de uma composição imunogênica |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008419-2A BR112015008419B1 (pt) | 2012-10-17 | 2013-10-15 | Composição imunogênica, vacina, e, uso de uma composição imunogênica ou de uma vacina |
| BR112015008417A BR112015008417A8 (pt) | 2012-10-17 | 2013-10-15 | composição imunogênica, vacina, e, uso de uma composição imunogênica |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP2908854A2 (https=) |
| JP (3) | JP6412500B2 (https=) |
| KR (2) | KR20150072444A (https=) |
| CN (2) | CN104968366B (https=) |
| AU (2) | AU2013331781A1 (https=) |
| BR (3) | BR112015008418A2 (https=) |
| CA (3) | CA2888321A1 (https=) |
| EA (2) | EA201590491A1 (https=) |
| ES (1) | ES2640320T3 (https=) |
| IL (2) | IL238053A0 (https=) |
| MX (2) | MX2015005002A (https=) |
| SG (2) | SG11201502634TA (https=) |
| WO (3) | WO2014060385A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201218660D0 (en) | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN104306965B (zh) * | 2014-10-31 | 2017-05-10 | 康希诺生物股份公司 | 预防肺炎链球菌感染性疾病的免疫原性组合物及制备方法 |
| KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| GB201518684D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| GB201603029D0 (en) * | 2016-02-22 | 2016-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| CN106432512B (zh) * | 2016-09-30 | 2022-03-01 | 康希诺生物股份公司 | 一种增强多糖抗原免疫原性蛋白载体及其制备方法与应用 |
| KR102905809B1 (ko) * | 2018-01-19 | 2025-12-30 | 오비아이 파머 인코퍼레이티드 | Crm197 단백질 발현 |
| CN110540597B (zh) * | 2018-12-20 | 2021-04-30 | 湖北工业大学 | 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法 |
| MY207887A (en) * | 2020-05-01 | 2025-03-26 | Sinocelltech Ltd | Method for improving immunogenicity of protein/peptide antigen |
| KR20220142219A (ko) * | 2021-04-14 | 2022-10-21 | 한국생명공학연구원 | 장내 미생물에서 단백질 분비를 유도하는 신호서열 |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| CN117512031B (zh) * | 2023-10-16 | 2024-06-25 | 江苏金迪克生物技术股份有限公司 | 一种肺炎球菌荚膜多糖的纯化方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE459373T1 (de) * | 1999-03-19 | 2010-03-15 | Glaxosmithkline Biolog Sa | Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae |
| CZ20024224A3 (cs) * | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| ATE557033T1 (de) * | 2003-12-23 | 2012-05-15 | Nationwide Children S Hospital Inc | Pili von haemophilus influenzae typ iv |
| ATE488526T1 (de) * | 2005-07-08 | 2010-12-15 | Nationwide Childrens Hospital | Chimärer impfstoff für haemophilus influenzae- induzierte infektion |
| MY150105A (en) * | 2006-01-17 | 2013-11-29 | Forsgren Arne | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
| CA2690708A1 (en) * | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine |
| MX2011006922A (es) * | 2008-12-24 | 2012-06-12 | Netherlands Vaccine Inst | Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia. |
| WO2011027257A2 (en) * | 2009-09-03 | 2011-03-10 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| AU2010335970B2 (en) * | 2009-12-22 | 2016-11-03 | Sanofi Pasteur Limited | Immunogenic compositions |
| MX2013006255A (es) * | 2010-12-03 | 2015-08-05 | Sanofi Pasteur Ltd | Composicion para inmunizacion contra streptococcus pneumoniae. |
| BR112013024322B1 (pt) * | 2011-03-22 | 2020-04-22 | Serum Inst India Ltd | processo para preparação de polissacarídeos |
| TW201302779A (zh) * | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| CN103533953A (zh) * | 2011-05-17 | 2014-01-22 | 葛兰素史密丝克莱恩生物有限公司 | 针对肺炎链球菌的疫苗 |
-
2013
- 2013-10-15 EA EA201590491A patent/EA201590491A1/ru unknown
- 2013-10-15 CA CA2888321A patent/CA2888321A1/en not_active Abandoned
- 2013-10-15 BR BR112015008418A patent/BR112015008418A2/pt not_active IP Right Cessation
- 2013-10-15 ES ES13779190.1T patent/ES2640320T3/es active Active
- 2013-10-15 CN CN201380066162.9A patent/CN104968366B/zh active Active
- 2013-10-15 BR BR112015008419-2A patent/BR112015008419B1/pt active IP Right Grant
- 2013-10-15 EP EP13776808.1A patent/EP2908854A2/en not_active Ceased
- 2013-10-15 CA CA2888300A patent/CA2888300A1/en not_active Abandoned
- 2013-10-15 BR BR112015008417A patent/BR112015008417A8/pt not_active Application Discontinuation
- 2013-10-15 MX MX2015005002A patent/MX2015005002A/es unknown
- 2013-10-15 SG SG11201502634TA patent/SG11201502634TA/en unknown
- 2013-10-15 WO PCT/EP2013/071477 patent/WO2014060385A1/en not_active Ceased
- 2013-10-15 CN CN201380066113.5A patent/CN104853768B/zh not_active Expired - Fee Related
- 2013-10-15 JP JP2015537218A patent/JP6412500B2/ja not_active Expired - Fee Related
- 2013-10-15 AU AU2013331781A patent/AU2013331781A1/en not_active Abandoned
- 2013-10-15 CA CA2888310A patent/CA2888310C/en active Active
- 2013-10-15 MX MX2015004949A patent/MX365842B/es active IP Right Grant
- 2013-10-15 SG SG11201502635SA patent/SG11201502635SA/en unknown
- 2013-10-15 KR KR1020157013039A patent/KR20150072444A/ko not_active Withdrawn
- 2013-10-15 AU AU2013333975A patent/AU2013333975A1/en not_active Abandoned
- 2013-10-15 KR KR1020157013037A patent/KR20150058571A/ko not_active Withdrawn
- 2013-10-15 EA EA201590490A patent/EA201590490A1/ru unknown
- 2013-10-15 JP JP2015537216A patent/JP6236086B2/ja active Active
- 2013-10-15 WO PCT/EP2013/071472 patent/WO2014060383A1/en not_active Ceased
- 2013-10-15 EP EP13779191.9A patent/EP2908856B1/en active Active
- 2013-10-15 WO PCT/EP2013/071483 patent/WO2014060389A2/en not_active Ceased
- 2013-10-15 EP EP13779190.1A patent/EP2908855B1/en active Active
- 2013-10-15 JP JP2015537220A patent/JP2015534964A/ja active Pending
-
2015
- 2015-03-31 IL IL238053A patent/IL238053A0/en unknown
- 2015-04-01 IL IL238079A patent/IL238079A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015008418A2 (pt) | uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae | |
| BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
| MX2021015775A (es) | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos. | |
| BR112015005772A2 (pt) | método para a intensificação de imunoterapias específicas no tratamento de câncer | |
| BR112015031883A2 (pt) | anti-pd-1 anticorpo e o uso dele | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| BR112014018815A8 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
| MX341684B (es) | Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel. | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| BR112015023797A2 (pt) | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 | |
| SA516371506B1 (ar) | تركيبات مولدة للمناعة مشتملة على مولدات مضاد ساكاريد كبسولية متقارنة واستخداماتها | |
| MX367241B (es) | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. | |
| BR112015030514A2 (pt) | Composições e métodos para conjugação de anticorpos ativáveis | |
| BRPI0813307B8 (pt) | composição imunogênica, vacina, e, processo para fabricar a vacina | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| BR112014003477A2 (pt) | composições imunoterapêuticas de levedura-muc1 e usos das mesmas | |
| BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| BR112014032999A2 (pt) | optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos | |
| BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112015013700A2 (pt) | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição | |
| HK1210714A1 (en) | Antibody formulations and uses thereof | |
| WO2014107652A3 (en) | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| MX2012001495A (es) | Polipeptidos de porphyromonas gingivalis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |